Wang Xia, Zhang Mei, Liu Zhi, Li Chuan, Li Yujue, Huang Hengjian, He He, Yu Xijie
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
Front Endocrinol (Lausanne). 2025 May 20;16:1506664. doi: 10.3389/fendo.2025.1506664. eCollection 2025.
Variability in biomarkers is crucial for clinical decision-making in individuals with type 2 diabetes mellitus (T2DM). The biological variation (BV) of biomarkers associated with thyroid function, iron metabolism, and bone metabolism may show population-specific differences. This study aims to evaluate the biological variation of sixteen biomarkers in T2DM patients and compare these with variations observed in a healthy population.
Twenty-four T2DM patients, aged 43 to 67 and in stable condition, were enrolled. Blood samples were collected biweekly for three months. Analysis of variance models were used to assess the BV, including within-subject BV (CV), between-subject BV (CV), analytical variation, reference change value (RCV), index of individuality (II), the number of samples required for steady-state set points (NHSP), and analytical performance specifications for all biomarkers.
Females exhibited lower CV estimates for thyroid-stimulating hormone, parathyroid hormone, and phosphate compared to males. No significant differences in CV estimates were observed between T2DM patients and healthy individuals across the study. However, the CV estimates for cortisol and iron were significantly lower in T2DM patients compared to the healthy individuals.
BV data is critical for the precise interpretation of serial biomarker level changes in T2DM patients. It is deemed reasonable to use RCVs for four bone metabolism markers and five thyroid biomarkers, derived from a healthy population, as a reference for monitoring T2DM patients.
生物标志物的变异性对于2型糖尿病(T2DM)患者的临床决策至关重要。与甲状腺功能、铁代谢和骨代谢相关的生物标志物的生物学变异(BV)可能存在人群特异性差异。本研究旨在评估T2DM患者中16种生物标志物的生物学变异,并将其与健康人群中观察到的变异进行比较。
纳入24例年龄在43至67岁之间且病情稳定的T2DM患者。每两周采集一次血样,共采集三个月。使用方差分析模型评估BV,包括受试者内BV(CV)、受试者间BV(CV)、分析变异、参考变化值(RCV)、个体性指数(II)、达到稳态设定点所需的样本数量(NHSP)以及所有生物标志物的分析性能规格。
与男性相比,女性促甲状腺激素、甲状旁腺激素和磷酸盐的CV估计值较低。在整个研究中,T2DM患者和健康个体之间的CV估计值未观察到显著差异。然而,与健康个体相比,T2DM患者中皮质醇和铁的CV估计值显著较低。
BV数据对于准确解释T2DM患者系列生物标志物水平变化至关重要。将来自健康人群的4种骨代谢标志物和5种甲状腺生物标志物的RCV用作监测T2DM患者的参考是合理的。